Cetrotide (cetrorelix) / EMD Serono - LARVOL DELTA

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (clinicaltrials.gov) - P3 | N=204 | Not yet recruiting | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

IVF ART: Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles. (clinicaltrials.gov) - P4 | N=230 | Not yet recruiting | Sponsor: Trust Fertility Clinic

First-in-human • Head-to-Head • New P4 trial

Crosstalk with the cholinergic pathway may be responsible for chlorpyrifos-induced reproductive toxicity in fish. (PubMed, Aquat Toxicol) - "Co-exposure to cetrorelix acetate, a potent GnRH receptor antagonist, has been demonstrated to normalize gene expression and restore E2 levels. These results suggest that CPF-induced reproductive toxicity involves crosstalk between cholinergic signaling and the HPG axis. These findings underscore the complex toxicity and ecological risks associated with CPF."

Journal • HSD3B1

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov) - P3 | N=333 | Not yet recruiting | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

New P3 trial • Infertility • Sexual Disorders

Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol. (PubMed, Hum Fertil (Camb)) - "This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles...The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol."

Clinical • HEOR • Journal • Retrospective data

Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer. (PubMed, Front Oncol) - "This mechanism was substantiated by the findings that the PI3K inhibitor LY294002 mimicked cetrorelix's effects without producing an additive apoptotic response, and that GnRHR knockdown abrogated cetrorelix-induced apoptosis, confirming receptor specificity. These findings suggest that cetrorelix may induce EOC apoptosis via the PI3K/AKT-FOXO1 pathway, which provides mechanistic support for the therapeutic potential of GnRH antagonists in EOC management. Moreover, the identified critical regulatory pathways are prospective therapeutic targets for EOC management."

Journal • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXO1

Cetrorelix suppresses the dominant follicle and synchronizes follicular waves and ovulation in cattle. (PubMed, Biol Reprod) - "Corpus luteum diameter was smaller (P=0.01) in the cetrorelix groups, but luteal vascularity, life-span, or progesterone production was not affected. In Experiment 3, cetrorelix given at random days of the cycle induced a new wave 3.4±0.3 days later and wave emergence was more synchronous than in saline-treated cows (Barlett's test P=0.04). Results supported hypotheses and provide rationale for the development of new cetrorelix-based protocols for breeding management in cattle."

Journal

Effect of a GnRH antagonist on the fate of the dominant ovarian follicle and the emergence of the next follicular wave in alpacas. (PubMed, Theriogenology) - "In conclusion, treatment with a single or double dose of 1.5 mg Cetrorelix caused the demise of dominant follicle leading to synchronous emergence of the next follicular wave 5 days (single dose) or 8 days (two doses) later. Results document the potential utility of Cetrorelix in breeding management protocols that enable pre-scheduled, synchronous insemination."

Journal

From Ovarian Hyperstimulation Syndrome (OHSS) to Cortical Necrosis: A Rare Renal Catastrophe (KIDNEY WEEK 2025) - "Case Description A 26-year-old woman with primary infertility underwent controlled ovarian stimulation using rFSH, hCG, and cetrorelix...Prompt initiation of fluids, albumin, vasopressors, and RRT is critical for managing this condition. With the increasing use of assisted reproduction, vigilant monitoring during ovarian stimulation is vital to prevent such outcomes."

Acute Kidney Injury • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Infertility • Metabolic Disorders • Nephrology • Obstetrics • Renal Disease • Septic Shock • Sexual Disorders • Thrombocytopenia

Substituting DDGS with soybean meal in finishing diets: Effects on small intestinal amino acid flow, digestibility, and nitrogen balance. (PubMed, J Anim Sci) - "Treatments were: 1) 15.0% DDGS (CON); 2) SBM in replacement of 50% of DDGS (SBM50); 3) SBM in replacement of 75% of DDGS (SBM75), and 4) SBM in replacement of 100% of DDGS (SBM100)...Ultimately, DDGS and SBM deliver similar metabolizable amino acids in beef cattle finishing diets. This allows producers to prioritize cost-effectiveness and regional availability when selecting a protein source."

Journal

Phoenixin-14 ameliorates acetic acid-induced ulcerative colitis in rats via antioxidant, anti-inflammatory and anti-apoptotic mechanisms. (PubMed, Peptides) - "The control group was treated intraperitoneally with saline, while the colitis groups were treated intraperitoneally with saline or PNX-14 (50 μg/kg/d) or gonadotrophin-releasing hormone (GnRH)-antagonist cetrorelix (CTX; 100µg/kg/d) or CTX and PNX-14 or sulfasalazine as a positive control (100mg/kg/d) instantly and once a day for 3 days following colitis induction. PNX-14, which alleviates macroscopic, histological and biochemical parameters, can be considered as a potential therapeutic agent in ulcerative colitis with its anti-inflammatory, antioxidant and anti-apoptotic actions. Furthermore, despite its effects as an GnRH-antagonist, CTX has also revealed a similar beneficial role as PNX-14 in this ulcerative colitis model."

Journal • Preclinical • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Oncology • Psychiatry • Ulcerative Colitis • CASP3 • CASP8 • CXCL8 • IFNG • IL6 • MPO • TNFA

Intranasal Delivery of Cetrorelix Via Lipid Liquid Crystal Nanoparticles: Characterization and Pharmacokinetic Studies in Rats. (PubMed, AAPS PharmSciTech) - "This study introduces, for the first time, a cetrorelix-loaded lipid liquid crystal (LLC) nanoparticle formulation for intranasal nose-to-brain delivery. The LLC system achieved enhanced brain targeting efficiency while reducing systemic exposure compared to conventional subcutaneous injections and simple nasal formulations, representing a promising advancement in GnRH drug delivery strategies."

Journal • PK/PD data • Preclinical

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (clinicaltrials.gov) - P=N/A | N=220 | Terminated | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | N=784 ➔ 220 | Trial completion date: Dec 2025 ➔ May 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2024 ➔ May 2025; The study was terminated due to difficulty in recruiting patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gynecology • Infertility • Sexual Disorders

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (clinicaltrials.gov) - P3 | N=204 | Not yet recruiting | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Polycystic Ovary Syndrome

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (clinicaltrials.gov) - P3 | N=400 | Completed | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ May 2025

Trial completion • Trial completion date

Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF (clinicaltrials.gov) - P=N/A | N=1338 | Recruiting | Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Trial primary completion date: Dec 2024 ➔ Dec 2025

Head-to-Head • Trial primary completion date • Infertility • Sexual Disorders

Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach. (PubMed, J Pept Sci) - "Controlling these impurities to the lowest possible levels is essential for developing an efficient preparative HPLC purification process for the commercial production of cetrorelix. This stringent control ensures that the final product meets the high standards required for commercial production and therapeutic use."

Journal

Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study. (PubMed, Front Reprod Health) - "Cetrorelix offering enhanced endometrial receptivity (66.2% Type A morphology) and safety advantages. These findings support cetrorelix's role in optimizing ART safety without compromising efficacy."

Journal • Retrospective data

Insights Into the Role of Leuconostoc Mesenteroides SB1075 Fermentation in Enhancing the Shelf-Life of Soy Yogurt. (PubMed, J Food Sci) - "PRACTICAL APPLICATION: Our research addresses a critical need in the food industry: prolonging the shelf life of soy yogurt without relying on preservatives, which is achieved using a plant-derived probiotic bacterium L. mesenteroides SB1075. The findings outlined in this manuscript propose an innovative and sustainable approach to improving the quality and shelf life of soy yogurt, meeting the increasing demand for vegan, healthier, and preservative-free food choices."

Journal

Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells. (PubMed, Biomed Pharmacother) - "Hecate-FSHβ33-53C/S is highly effective in selectively targeting and killing FSHR-expressing cancer cells, with minimal side effects, suggesting its potential as a therapeutic option for cancers expressing FSH receptors."

Journal • Genito-urinary Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • FSHB

Effect of premature luteinizing hormone surge on pregnancy outcomes in intracytoplasmic sperm injection or in vitro fertilization cycles. (PubMed, Front Med (Lausanne)) - "With regard to the number of oocytes collected, M2, and fertilization rate, these were significantly higher in women without premature LH surge, with p-values of 0.001, 0.002, and 0.004, respectively. The study demonstrates significantly higher live birth rates in women without premature LH surge."

Journal • Preclinical • Gynecology

Dydrogesterone is an eligible tool to suppress LH surge in assisted reproduction technologies (ART) cycles. (PubMed, JBRA Assist Reprod) - "DYG is an eligible tool for IVF/ICSI cycles intended to freeze-all and oocyte preservation, embryo banking, and preventing OHSS in patients with high AMH levels."

Journal • Endometriosis • Gynecology • Women's Health

PPOS vs GnRH: PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial (clinicaltrials.gov) - P3 | N=328 | Completed | Sponsor: Kasr El Aini Hospital

New P3 trial

Follicular Long GnRH Agonist Versus Antagonist Protocol in PCOS Women Undergoing in Vitro Fertilization (clinicaltrials.gov) - P=N/A | N=1266 | Completed | Sponsor: The First Affiliated Hospital of Zhengzhou University | Unknown status ➔ Completed | N=50 ➔ 1266 | Trial completion date: Aug 2018 ➔ Dec 2024

Enrollment change • Trial completion • Trial completion date • Gynecology • Polycystic Ovary Syndrome

PROGESTERONE-PRIMED OVARIAN STIMULATION VERSUS GONADOTROPHIN-RELEASING HORMONE ANTAGONIST in WOMEN with POLYCYSTIC OVARIAN SYNDROME (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: El Shatby University Hospital for Obstetrics and Gynecology

New trial • Polycystic Ovary Syndrome